Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2021 | $16.00 | Buy | HC Wainwright & Co. |
TORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's board of directors has appointed Stephen Lemieux, CPA to the role of Chief Financial Officer, effective July 15, 2023. He is a veteran of the healthcare and biopharmaceutical sectors, with more than 20 years of experience in financial planning and analysis, licensing and mergers & acquisitions."Stephen joins Edesa at an exciting time as we build on our regulatory and clinical achievements and set our sights on additional growth opportunities. He shares our disciplined, manage-like-owner
TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of Jennifer M. Chao to the company's Board of Directors."Ms. Chao's appointment to our Board comes at an exciting time as we prepare for the most meaningful milestones yet in our clinical programs. Her extensive experience in the life science sector and capital markets will be a valuable resource to Edesa and its shareholders," said Par Nijhawan, MD, Chief Executive Officer of Edesa.Ms. Chao has more than 25 years of experience in the biotech and life sciences industries focused primarily
TORONTO, ON / ACCESSWIRE / June 23, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of a key member to its management team to support the company's expanding manufacturing activities.Rajan Puri has been appointed to the newly established position of Senior Vice President of Manufacturing. Mr. Puri is an expert in Chemistry, Manufacturing and Controls (CMC) in the biopharmaceutical field and will lead the company's strategic planning and operations related to scale-up, manufacturing and quality control."We are pleased to welcome Raj to our management team in anticipation o
SC 13D/A - Edesa Biotech, Inc. (0001540159) (Subject)
SC 13G - Edesa Biotech, Inc. (0001540159) (Subject)
SC 13G/A - Edesa Biotech, Inc. (0001540159) (Subject)
8-K - Edesa Biotech, Inc. (0001540159) (Filer)
424B5 - Edesa Biotech, Inc. (0001540159) (Filer)
8-K - Edesa Biotech, Inc. (0001540159) (Filer)
TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that the company has entered into a purchase agreement with an entity affiliated with Par Nijhawan, MD, Edesa's Chief Executive Officer and Founder, to invest up to $5.0 million in the company, including an immediate investment of approximately $1.5 million. The entity will purchase shares of the company's Series A-1 Convertible Preferred Shares, as amended (the "Series A-1 Preferred Shares"), having a stated value of $10,000 per share, and warrants (the "Warrants") to pur
TORONTO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business development staff plan to participate in the following upcoming conferences: BIO-Europe, Stockholm, Sweden, November 4-6, 2024Dermatology Drug Development Summit, Boston, Mass., November 12-14, 2024LSX Investival Showcase, London, UK, November 18, 2024 To schedule a meeting with Edesa during the conferences, please contact conference organizers or the company directly at [email protected]. About Edesa Biotech, Inc. Edesa Biote
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2024 and provided an update on its business. During the quarter, the company's anti-TLR4 drug candidate, EB05 (paridiprubart), was selected by the U.S. Department of Health and Human Services for use in a U.S. government-funded platform study investigating novel threat-agnostic host-directed therapeutics in patients with Acute Respiratory Distress Syndrome (ARDS). Edesa is providing drug product for the trial as
4 - Edesa Biotech, Inc. (0001540159) (Issuer)
HC Wainwright & Co. initiated coverage of Edesa Biotech with a rating of Buy and set a new price target of $16.00
HC Wainwright & Co. analyst Vernon Bernardino reiterates Edesa Biotech (NASDAQ:EDSA) with a Buy and maintains $21 price target.
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes.This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS.Paridiprubart was selected following a competitive review process of multiple host-directed therapeutic candidates.TORONTO, ON / ACCESSWIRE / June 24, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics (HDTs) for immuno-inflammatory diseases, announced today that its first-in-class drug candidate has been selected by the Biomedical Advance
4 - Edesa Biotech, Inc. (0001540159) (Issuer)
4 - Edesa Biotech, Inc. (0001540159) (Issuer)
4 - Edesa Biotech, Inc. (0001540159) (Issuer)